Myasthenia Gravis - Pipeline Review, H2 2011

Myasthenia Gravis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Myasthenia Gravis - Pipeline Review, H2 2011', provides an overview of the Myasthenia Gravis therapeutic pipeline. This report provides information on the therapeutic development for Myasthenia Gravis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myasthenia Gravis. 'Myasthenia Gravis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myasthenia Gravis.
- A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Myasthenia Gravis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Myasthenia Gravis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Myasthenia Gravis Therapeutic Products under Development, Key Players in Myasthenia Gravis Therapeutics, Myasthenia Gravis Pipeline Overview, Myasthenia Gravis Pipeline, Myasthenia Gravis Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis Overview
Therapeutics Development
An Overview of Pipeline Products for Myasthenia Gravis
Myasthenia Gravis Therapeutics under Development by Companies
Myasthenia Gravis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Myasthenia Gravis Therapeutics - Products under Development by Companies
Myasthenia Gravis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Myasthenia Gravis Therapeutics Development
Accentia Biopharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Cytokinetics, Inc
Tolerx, Inc.
Bayhill Therapeutics, Inc.
Myasthenia Gravis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Otelixizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Soliris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CK-2017357 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revimmune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BHT-3034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mabthera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CK-2066260 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myasthenia Gravis Therapeutics – Drug Profile Updates
Myasthenia Gravis Therapeutics - Discontinued Products
Myasthenia Gravis - Featured News
Sep 26, 2011: Mitsubishi Announces Approval For Venoglobulin IH For Additional Indication Of Generalized Myasthenia Gravis
Sep 14, 2011: Phase II Study of Eculizumab In Patients With Severe And Refractory Generalized Myasthenia Gravis Presented At MGFA Annual Meeting
Apr 11, 2011: Cytokinetics To Present Phase IIa Clinical Trial Data Of CK-2017357 In Amyotrophic Lateral Sclerosis At 63rd Annual Meeting Of American Academy of Neurology
Mar 01, 2011: Bayhill Therapeutics Announces Successful Clearance Of IND For BHT-3034 For Treatment of Myasthenia Gravis
Jan 04, 2011: Cytokinetics Opens Enrollment In Phase IIa Myasthenia Gravis Trial Of CK-2017357
Jul 26, 2010: Cytokinetics Receives $2.9 Million For Preclinical And Clinical Development Of CK-2017357 In Myasthenia Gravis
Aug 06, 2009: European Commission And U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation For The Treatment Of Atypical Hemolytic Uremic Syndrome (aHUS)
Feb 28, 2007: Accentia Biopharmaceuticals Acquires Worldwide Exclusive License To Revimmune
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Myasthenia Gravis, H2 2011
Products under Development for Myasthenia Gravis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Accentia Biopharmaceuticals, Inc., H2 2011
Alexion Pharmaceuticals, Inc., H2 2011
Cytokinetics, Inc, H2 2011
Tolerx, Inc., H2 2011
Bayhill Therapeutics, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Myasthenia Gravis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Myasthenia Gravis, H2 2011
Products under Development for Myasthenia Gravis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011